Importance of microenvironment in preclinical models of breast and prostate cancer

doi:10.5497/wjp.v4.i1.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10178)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

704

WORD

461

HTML

5419

Figures (1-1)

289

Tables (1-3)

274

Sum=7147

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1307

Download

1724

Sum=3031

Mar 9, 2015 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Mar 9, 2015; 4(1): 47-57
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.47

Table 1 Classification of the most commonly used human breast cancer cell lines

Name	Histopathologicalclassification	Immunohistochemicalclassification
MCF-7	Luminal A	ER⁺, PR⁺, Her2^-
SUM185	Luminal A	ER⁺, PR^-, Her2^-
T47D	Luminal A	ER⁺, PR⁺, Her2^-
BT-474	Luminal B	ER⁺, PR⁺, Her2⁺
ZR-75	Luminal B	ER⁺, PR^-, Her2⁺
SKBR3	Her2-positive	ER^-, PR^-, Her2⁺
MDA-MB-453	Her2-positive	ER^-, PR^-, Her2⁺
MDA-MB-468	Basal	ER^-, PR^-, Her2^-
SUM190	Basal	ER^-, PR^-, Her2⁺
BT-20	Basal	ER^-, PR^-, Her2^-
MDA-MB-231	Claudin-low	ER^-, PR^-, Her2^-
HS-578T	Claudin-low	ER^-, PR^-, Her2^-
Cal-51	Claudin-low	ER^-, PR^-, Her2^-

Adapted from a review of Holliday and Speirs 2011[24]. ER^+/-: Estrogen receptor-positive/negative; PR^+/-: Progesterone receptor-positive/negative; Her2^+/-: Human epidermal growth factor-positive/negative.

Citation: Valta M, Fagerlund K, Suominen M, Halleen J, Tuomela J. Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 2015; 4(1): 47-57
URL: https://www.wjgnet.com/2220-3192/full/v4/i1/47.htm
DOI: https://dx.doi.org/10.5497/wjp.v4.i1.47